Furamag, capsules 25 mg 30 pcs

Furamag is a broad-spectrum antimicrobial agent belonging to the group of nitrofurans.

Resistance to Furamag develops slowly and does not reach a high degree.

Active against Gram-positive cocci: Streptococcus spp., Staphylococcus spp.; Gram-negative bacilli: Escherichia coli, Salmonella spp., Shigella spp., Proteus mirabilis, Klebsiella spp, Enterobacter spp.; protozoa: Lamblia intestinalis and other microorganisms resistant to antibiotics.

With regard to Staphylococcus spp, Escherichia coli, Aerobacter aerogenes, Leuconostoc citrovorum, Proteus mirabilis, Proteus morganii Furamag® is more active than other nitrofurans.

Against most bacteria, the bacteriostatic concentration is 1:100,000 to 1:200,000. Bactericidal concentration is about 2 times higher.

Under the influence of nitrofurans in microorganisms the respiratory chain and tricarboxylic acid cycle (Krebs cycle) is suppressed and other biochemical processes of microorganisms are inhibited, resulting in destruction of their shell or cytoplasmic membrane.

As a result of the action of nitrofurans microorganisms release fewer toxins, so that improvement of the overall condition of the patient is possible even before a pronounced suppression of microflora growth. Nitrofurans activate the body’s immune system: they increase the complement titer and the ability of leukocytes to phagocytize microorganisms. Furazidine in therapeutic doses stimulates leukopoiesis.

Indications

Infections caused by microorganisms sensitive to furazidin: urogenital infections (acute cystitis, urethritis, pyelonephritis), skin and soft tissue infections, severe infected burns, gynecological infections. Can be used prophylactically during urological operations, cystoscopy, catheterization, etc.

Pharmacological effect

A broad-spectrum antimicrobial agent belonging to the nitrofuran group. Resistance to Furamag develops slowly and does not reach a high degree.
Effective against gram-positive cocci (Staphylococcus spp., Streptococcus spp.), gram-negative bacilli (E. coli, Salmonella spp., Shigella spp., Klebsiella spp., Enterobacter). Plasmodium aeruginosa, Enterococcus spp., Acinetobacter spp., most strains of Proteus spp., Serratia spp. are resistant. The mechanism of action is associated with inhibition of nucleic acid synthesis. Depending on the concentration, it has a bactericidal or bacteriostatic effect. In relation to Staphylococcus spp., E.coli, Aerobacter aerogenes, Bact. Citrovorum, Proteus mirabilis, Proteus morganii Furamag, compared to other nitrofurans, is more active. Furamag exhibits higher activity against Enterococcus faecalis, Staphylococcus spp. compared to other groups of antimicrobial drugs.
Against most bacteria, the bacteriostatic concentration ranges from 1:100,000 to 1:200,000. The bactericidal concentration is approximately twice as high. Under the influence of nitrofurans in microorganisms, the respiratory chain and the tricarboxylic acid cycle (Krebs cycle) are suppressed, as well as other biochemical processes of microorganisms are suppressed, resulting in the destruction of their shell or cytoplasmic membrane. As a result of the action of nitrofurans, microorganisms produce fewer toxins, and therefore an improvement in the general condition of the patient is possible even before a pronounced suppression of the growth of microflora.

Active ingredient

Furazidin

Composition

1 capsule contains:
active ingredient – potassium furazidin 25.00 mg;
excipients – magnesium hydroxycarbonate 25.00 mg, corn starch 1.25 mg, talc 1.50 mg, sodium stearyl fumarate 0.25 mg;
hard gelatin capsules No. 4: titanium dioxide (E171) 3.0000%, iron dye yellow oxide (E172) 0.7333%, gelatin up to 100%.

Contraindications

-Hypersensitivity to furazidine, drugs of the nitrofuran group, other excipients
-severe chronic renal failure (glomerular filtration rate less than 30 ml/min)
-pregnancy
-breastfeeding period
-polyneuropathy (including diabetic)
-porphyria
-children under 18 years of age

With caution:
-Glucose-6-phosphate dehydrogenase deficiency
-impaired kidney function of mild to moderate severity, liver
-anemia
– deficiency of B vitamins and folic acid
-lung diseases (especially in patients over 65 years of age)
-diabetes mellitus

Side Effects

Blood and lymphatic system disorders
agranulocytosis, thrombocytopenia, aplastic anemia
Immune system disorders
pruritus, papular rash, angioedema, urticaria, exfoliative dermatitis, erythema multiforme
Nervous system disorders
dizziness, headache, drowsiness, peripheral neuropathy
Visual disorders
visual impairment
Vascular disorders
intracranial hypertension
Disorders of the respiratory system, chest and mediastinal organs
acute or chronic reaction from the lungs. An acute reaction from the lungs develops quickly and manifests itself in the form of acute shortness of breath, fever, chest pain, cough without sputum, eosinophilia (reversible after discontinuation of the drug). Skin rash, itching, urticaria, angioedema and myalgia have also been reported. Chronic pulmonary reaction may occur over a long period of time after discontinuation of treatment and is characterized by a gradual increase in dyspnea, increased respiratory rate, intermittent fever, eosinophilia, progressive cough and interstitial pneumonitis and/or pulmonary fibrosis
Gastrointestinal disorders
nausea, vomiting, loss of appetite, diarrhea, pancreatitis
Disorders of the liver and biliary tract
cholestatic jaundice, hepatitis
Musculoskeletal and connective tissue disorders
arthralgia
General disorders and disorders at the site of administration
frequency unknown: fever, weakness, reversible alopecia, urine dark yellow or brown

Interaction

Furamag should not be used together with ristomycin, chloramphenicol, sulfonamides (the risk of hematopoietic suppression increases).
During the treatment period, it is advisable to refrain from drinking alcoholic beverages, because side effects may increase.
It is not recommended to prescribe drugs that can “acidify” urine (including ascorbic acid, calcium chloride) simultaneously with nitrofurans.

Overdose

In case of overdose, symptoms of a neurotoxic nature, ataxia and tremor are observed.
In case of poisoning, drink plenty of liquid. Antihistamines are used to relieve acute symptoms. To prevent neuritis, it is possible to prescribe vitamins (thiamine bromide).

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 ° C.
Keep out of the reach of children.

Shelf life

3 years

Manufacturer

Olainfarm, Latvia